Biopsy muscle perq needle

CPT code 20206 covers a percutaneous (through the skin) needle biopsy of muscle tissue. A physician inserts a needle through the skin to extract a small muscle sample for laboratory analysis to diagnose muscle disorders or diseases.

Showing rates for

National Average

Base Medicare rate

$206.37

This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.

RVU breakdown

Work RVU

0.99

PE RVU (NF)

5.29

MP RVU

0.1

Total RVU

6.38

Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High

NCCI bundling edits

Loading bundling edits…

Billing tips

Verify place of service carefully - the reimbursement differential between non-facility ($206.37) and facility ($55.31) settings is $151.06, representing a 273% difference
Impact: Billing with incorrect POS code can result in $151.06 underpayment or overpayment requiring refund and potential audit
Document the specific muscle biopsied with anatomical precision (e.g., 'left vastus lateralis' not just 'thigh muscle') to support medical necessity and prevent denials
Impact: Vague documentation is the leading cause of denials for this code, resulting in 100% payment loss and costly appeals
When multiple muscle sites are biopsied, append modifier 59 or XS to subsequent biopsies and clearly document each distinct anatomical location
Impact: Proper modifier use can increase reimbursement by 100% or more when multiple sites are medically necessary
If imaging guidance (ultrasound 76942 or CT 77012) is used, bill separately as these are not bundled with 20206
Impact: Additional $50-150 in reimbursement for properly documented image-guided procedures
Link diagnosis codes that clearly establish medical necessity (M60-M63 myopathies, G71-G73 muscle diseases, R25.2 cramp/spasm, R63.6 insufficient weight gain)
Impact: Weak or unrelated diagnosis codes trigger 30-40% of initial denials, delaying payment 45-90 days
Confirm pathology processing is ordered separately; 20206 covers only the biopsy procedure, not the specimen analysis (88302-88309)
Impact: Pathology services represent additional revenue of $100-500 depending on complexity; ensure separate billing

Live Field Datano reports yet

Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.

Working with CPT 20206?

Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.

Help build the field knowledge

MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.

Related actions

Frequently asked questions

What is the Medicare reimbursement rate for CPT 20206 in 2025?

The 2025 Medicare national average reimbursement for CPT 20206 is $206.37 in the non-facility setting and $55.31 in the facility setting. The facility rate is lower because the hospital or ASC receives separate facility fees. Actual payment may vary based on geographic locality adjustments.

Can CPT 20206 be billed with an E/M code on the same day?

Yes, CPT 20206 can be billed with an E/M service on the same day if the E/M represents a separately identifiable service beyond the typical evaluation for the biopsy. Modifier 25 must be appended to the E/M code, and documentation must clearly show the distinct nature of the evaluation and management service.

What is the difference between CPT 20206 and 20205?

CPT 20206 is for percutaneous needle muscle biopsy, while CPT 20205 is for deep muscle biopsy. Code 20205 involves a deeper or more extensive tissue sampling, often requiring larger instruments or more complex access, whereas 20206 is specifically for needle-based sampling through the skin.

How many RVUs is CPT code 20206 worth?

CPT 20206 has a total RVU value of 6.38 for 2025, consisting of 0.99 work RVUs, 5.29 non-facility practice expense RVUs (0.62 facility PE RVUs), and 0.10 malpractice RVUs. These values are from the CMS Physician Fee Schedule RVU25A released December 23, 2024.

Can you bill CPT 20206 bilaterally with modifier 50?

Yes, modifier 50 can be used when percutaneous muscle biopsies are performed on bilateral symmetrical muscles during the same session (e.g., both vastus lateralis muscles). Documentation must clearly indicate the medical necessity for bilateral sampling and specify each muscle biopsied. Reimbursement typically increases to 150% of the unilateral rate, though payer policies vary.

Is imaging guidance included in CPT 20206?

No, imaging guidance is not included in CPT 20206. If ultrasound guidance is used, separately report CPT 76942. If CT guidance is used, report CPT 77012. These imaging codes are not bundled with 20206 and should be billed separately when imaging is used to guide needle placement, with appropriate documentation of the imaging component.

What diagnosis codes support medical necessity for CPT 20206?

Common diagnosis codes supporting CPT 20206 include M60-M63 series (myopathies), G71-G73 series (muscular dystrophies and myopathies), M79.1 (myalgia), M62.81 (muscle weakness), R53.1 (weakness), and R73.01 (elevated CK). The diagnosis must demonstrate why muscle tissue analysis is necessary for diagnosis or treatment planning, supported by clinical findings and prior diagnostic workup.